Evidence map›Paper›PMID 39966387›Full record

ArticleCell death discovery2025

Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitors.

Lenka Daumova, Dmitry Manakov, Jiri Petrak, Dana Sovilj, Matej Behounek, Ladislav Andera, Ondrej Vit, Olga Souckova, Ondrej Havranek, Alex Dolnikova and 9 more

Abstract read
In one paragraph

Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lenka DaumovaInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.ORCID http://orcid.org/0000-0001-9141-3027
Dmitry ManakovInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Jiri PetrakBIOCEV Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Vestec, Czech Republic.ORCID http://orcid.org/0000-0002-8695-4803
Dana SoviljInstitute of Biotechnology, Czech Academy of Sciences / BIOCEV, Vestec, Czech Republic.
Matej BehounekBIOCEV Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Vestec, Czech Republic.
Ladislav AnderaInstitute of Biotechnology, Czech Academy of Sciences / BIOCEV, Vestec, Czech Republic.
Ondrej VitBIOCEV Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Vestec, Czech Republic.ORCID http://orcid.org/0000-0002-7941-0699
Olga SouckovaOMICS Mass Spectrometry Core Facility, Biology Departments, BIOCEV, Faculty of Science, Charles University, Vestec, Czech Republic.
Ondrej HavranekBIOCEV Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Vestec, Czech Republic.ORCID http://orcid.org/0000-0001-5826-3557
Alex DolnikovaInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Nicol RenesovaInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Liliana TuskovaInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Lucie WinkowskaCLIP, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Nardjas BettazovaInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Kristyna KupcovaBIOCEV Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Vestec, Czech Republic.
Marie Hubalek KalbacovaInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Miriama SikorovaInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.ORCID http://orcid.org/0009-0005-9025-1640
Marek TrnenyFirst Department of Medicine- Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Pavel KlenerInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. pavel.klener2@lf1.cuni.cz.ORCID http://orcid.org/0000-0001-7786-9378

Funding

Agentura Pro Zdravotnický Výzkum České Republiky (Czech Health Research Council) NU23-01-00323Agentura Pro Zdravotnický Výzkum České Republiky (Czech Health Research Council) NU23-03-00172Grantová Agentura České Republiky (Grant Agency of the Czech Republic) GA23-05474SGrantová Agentura, Univerzita Karlova (Charles University Grant Agency) GAUK 406822Leukemia and Lymphoma Society (Leukemia & Lymphoma Society) MCL 7005-24Univerzita Karlova v Praze (Charles University) SVV 260634Univerzita Karlova v Praze (Charles University) SVV260634Univerzita Karlova v Praze (Charles University) SVV No. 260637
6 · The paper itself

Abstract

A large body of evidence suggests that hypoxia drives aggressive molecular features of malignant cells irrespective of cancer type. Non-Hodgkin lymphomas (NHL) are the most common hematologic malignancies characterized by frequent involvement of diverse hypoxic microenvironments. We studied the impact of long-term deep hypoxia (1% O2) on the biology of lymphoma cells. Only 2 out of 6 tested cell lines (Ramos, and HBL2) survived ≥ 4 weeks under hypoxia. The hypoxia-adapted (HA)b Ramos and HBL2 cells had a decreased proliferation rate accompanied by significant suppression of both oxidative phosphorylation and glycolytic pathways. Transcriptome and proteome analyses revealed marked downregulation of genes and proteins of the mitochondrial respiration complexes I and IV, and mitochondrial ribosomal proteins. Despite the observed suppression of glycolysis, the proteome analysis of both HA cell lines showed upregulation of several proteins involved in the regulation of glucose utilization including the active catalytic component of prolyl-4-hydroxylase P4HA1, an important druggable oncogene. HA cell lines demonstrated increased transcription of key regulators of auto-/mitophagy, e.g., neuritin, BCL2 interacting protein 3 (BNIP3), BNIP3-like protein, and BNIP3 pseudogene. Adaptation to hypoxia was further associated with deregulation of apoptosis, namely upregulation of BCL2L1/BCL-XL, overexpression of BCL2L11/BIM, increased binding of BIM to BCL-XL, and significantly increased sensitivity of both HA cell lines to A1155463, a BCL-XL inhibitor. Finally, in both HA cell lines AKT kinase was hyperphosphorylated and the cells showed increased sensitivity to copanlisib, a pan-PI3K inhibitor. In conclusion, our data report on several shared mechanisms of lymphoma cell adaptation to long-term hypoxia including: 1. Upregulation of proteins responsible for glucose utilization, 2. Degradation of mitochondrial proteins for potential mitochondrial recycling (by mitophagy), and 3. Increased dependence on BCL-XL and PI3K-AKT signaling for survival. In translation, inhibition of glycolysis, BCL-XL, or PI3K-AKT cascade may result in targeted elimination of HA lymphoma cells.

Identifiers

PMID39966387
PMCPMC11836139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.